



Cornerstone
Medical
Education

AA[®]CME
AMERICAN ACADEMY OF CME, INC.

An Expert Appraisal of the Latest Science and the Evolving Treatment Landscape in ATTR: Achieving Outcomes Synergy at the Cardiologist-Neurologist Interface



Cornerstone
Medical
Education

AA[®]CME
AMERICAN ACADEMY OF CME, INC.

Presented by Cornerstone Medical Education, LLC.
This activity is supported through an independent educational
grant from AstraZeneca and Ionis Pharmaceuticals.

Faculty & Planner/Reviewer Disclosures

- **Sami Khella, MD**
 - **Advisory Board/Consultant:** Alnylam, AstraZeneca, Ionis, Alexion, Pfizer, BridgeBio
- **Ahmad Masri, MD, MS**
 - **Advisory Board/Consultant:** Akros, Alexion, Alnylam, Attralus, AstraZeneca, BioMarin, BMS, Cytokinetics, Eidos/BridgeBio, Haya, Ionis, Lexicon, Pfizer, Prothena, Tenaya
 - **Grant/Research Support:** Attralus, Cytokinetics, Ionis, Pfizer
- **Noel Dasgupta, MD, FACC**
 - **Advisory Board/Consultant:** Alnylam, AstraZeneca, BridgeBio, Novo Nordisk



- **Grant/Research Support:** Alnylam, AstraZeneca, Alexion, Intellia, Ionis, Novo Nordisk
- **Morie Gertz, MD, MACP**
 - **Advisory Board/Consultant:** AbbVie, Alexion, Alnylam, AstraZeneca, Dava Oncology, Ionis, Janssen, Johnson & Johnson, Medscape, Prothena, Sanofi
- **Senthil Selvaraj, MD, MS, MA**
 - **Advisory Board/Consultant:** AstraZeneca, BridgeBio
- **Ani Nalbandian, MD, MPH**
 - **Reports no relevant disclosures**
- **Clinical content has been reviewed for fair balance and scientific objectivity, and all relevant relationships listed have been mitigated**
- **All planners and reviewers have no relevant relationships**
- **This educational activity will not review off-label utilization of currently available therapies in ATTR, but will review the prospective role and potential uses of investigational agents if and when they are FDA-approved.**